Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Date:3/12/2009

II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial for patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
2. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
8. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
9. AMA Foundation Announces Seed Grant Research Recipients
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Innovations, LLC, a leading developer and marketer of high ... of their new European office in Enschede, the Netherlands ... management team and new European staff, local Enschede dignitaries ... of Economic Affairs in The Netherlands and Mr. Jan ...
... 31, 2011 Omni Bio Pharmaceutical, Inc. (OTC BB: OMBP), ... To the Shareholders of Omni Bio Pharmaceutical, Inc.: ... first month as the Chief Executive Officer of Omni Bio ... a close, this is an appropriate juncture to update our ...
Cached Medicine Technology:Freedom Innovations Opens New European Headquarters 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 3Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 4Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 5Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 6
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has presented its ... site-wide wedding gown promotion. , For those who ... unexpected way, the collection should be a great choice. The ... and they are available with custom service. , Now, all ... up to 75% off; most of them come in hot ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A lab ... Prevention may have been exposed to the Ebola virus ... And up to a dozen other lab workers ... late Wednesday afternoon. The possible exposure occurred Monday ... a sample of the potentially lethal virus to another ...
Breaking Medicine News(10 mins):Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... for Helicobacter pylori as the decay-accelerating factor (DAF), a ... , Blocking this interaction could lead to new drugs ... gastric cancer. The research appears as the ‘Paper of ... Journal of Biological Chemistry, an American Society for Biochemistry ...
... In a new clinical development partnership being launched ... arm, Cancer Research Technology (CRT) plans to take ... for not showing enough commercial promise following their ... new treatments from anti-cancer drugs that have been ...
... by the defence attorneys of the AIIMS hospital, has sought ... where a boy, suffering from cancer, got inflicted with AIDS ... ,The victim, who was nine years old at the ... for treatment of cancer, supposedly has contracted HIV due to ...
... drug Zoloft (sertraline) may avoid in preventing recurring of ... interval between the depressive episodes. ,One in every ... the study, reports foodconsumer.org. ,Researchers studied 152 ... recovered from depression during treatment with Zoloft -- 79 ...
... recent conducted at University of Michigan Health Systems in ... greater expectations of doom from their screening //mammography for ... not these expectations were unusually high or unrealistic. ... an outpatient clinic for screening mammography. The participants were ...
... Computer keyboards used in hospitals are a reservoir for ... to be disinfected every day, a new study warns.// ... various locations inside University of North Carolina hospitals and ... two types of bacteria, reports the science portal HealthCentral. ...
Cached Medicine News:Health News:Receptor for H.pylori Identified in Stomach 2Health News:Cancer Research UK Offers New Hope To Cancer Patients 2Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:Computer Keyboards In Hospitals Could Spread Infection To Patients 2
... a convenient, reusable, patient-friendly and effective ... orthopedic conditions/instabilities. These products are designed ... lateral to medial influence of cutaneous ... and soft tissue structures. Maximum benefit ...
... state-of-the-art laser scanning technology for an anatomically-contoured, ... lean, athletic legs. Offering the same ... Flex Sport's "second skin" fit conforms to ... no other off-the-shelf knee brace., ,Indications: ...
... Drytex Adjustable Patella Donut is a ... nylon core and polyester Lycra Fabric ... trimable full-circumference donut provides for patellar ... neoprene based allergies or irritations. Click ...
... of the Custom Montana2 alleviates the ... three-point load across the knee joint, ... area. The Diagonal Loading Strap gives ... the load to accommodate their daily ...
Medicine Products: